NCT03972501

An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)

A Single-center, Vehicle-controlled, Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZR-MD-001 as Adjunctive Therapy to Conventional Therapeutic Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Azura Ophthalmics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

SOVS2019-070 is a single-center study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD).

Detailed description

SOVS2019-070 is a single-center, single-masked (the individual(s) performing efficacy measures will be masked to treatment assignment for the patient(s) they are assessing), vehicle-controlled, randomized, parallel group study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD).

Conditions

• Meibomian Gland Dysfunction (MGD)
• Contact Lens Discomfort (CLD)

Interventions

Type	Name	Description
DRUG	AZR-MD-001 Vehicle	AZR-MD-001 is an ophthalmic ointment
DRUG	AZR-MD-001 Active Dose	AZR-MD-001 is an ophthalmic ointment

Timeline

• Start date: 2019-10-04
• Primary completion: 2020-12-11
• Completion: 2020-12-11
• First posted: 2019-06-03
• Last updated: 2023-01-25
• Results posted: 2023-01-25

Locations

1 site across 1 country: Australia